Swiss National Bank increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 1.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 165,600 shares of the biotechnology company’s stock after buying an additional 1,600 shares during the quarter. Swiss National Bank owned approximately 383,244.62% of United Therapeutics Corporation worth $19,407,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in UTHR. Oregon Public Employees Retirement Fund lifted its holdings in United Therapeutics Corporation by 9.0% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 33,598 shares of the biotechnology company’s stock valued at $3,937,000 after purchasing an additional 2,767 shares during the last quarter. American Century Companies Inc. lifted its holdings in United Therapeutics Corporation by 3.7% during the 3rd quarter. American Century Companies Inc. now owns 15,779 shares of the biotechnology company’s stock valued at $1,849,000 after purchasing an additional 567 shares during the last quarter. State of Tennessee Treasury Department lifted its holdings in United Therapeutics Corporation by 21.3% during the 3rd quarter. State of Tennessee Treasury Department now owns 56,900 shares of the biotechnology company’s stock valued at $6,668,000 after purchasing an additional 10,000 shares during the last quarter. State of Wisconsin Investment Board lifted its holdings in United Therapeutics Corporation by 11.5% during the 3rd quarter. State of Wisconsin Investment Board now owns 45,159 shares of the biotechnology company’s stock valued at $5,292,000 after purchasing an additional 4,644 shares during the last quarter. Finally, Old Mutual Global Investors UK Ltd. lifted its holdings in United Therapeutics Corporation by 30.3% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 970,846 shares of the biotechnology company’s stock valued at $113,773,000 after purchasing an additional 225,953 shares during the last quarter.

United Therapeutics Corporation (NASDAQ:UTHR) opened at $123.02 on Friday. United Therapeutics Corporation has a 12-month low of $112.01 and a 12-month high of $169.89. The company has a market capitalization of $5,315.82, a price-to-earnings ratio of 10.85 and a beta of 1.38.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, topping the Zacks’ consensus estimate of $4.01 by $2.26. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The company had revenue of $445.50 million for the quarter, compared to analysts’ expectations of $426.43 million. During the same quarter last year, the business earned $4.23 earnings per share. United Therapeutics Corporation’s revenue was up 9.1% on a year-over-year basis. equities analysts forecast that United Therapeutics Corporation will post 12.29 earnings per share for the current fiscal year.

WARNING: “United Therapeutics Corporation (UTHR) Stake Raised by Swiss National Bank” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/united-therapeutics-corporation-uthr-stake-raised-by-swiss-national-bank/1713651.html.

In related news, CEO Martine A. Rothblatt sold 7,061 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $121.12, for a total value of $855,228.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 1,238 shares of the firm’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $130.65, for a total value of $161,744.70. Following the completion of the sale, the chief executive officer now directly owns 2,307 shares in the company, valued at $301,409.55. The disclosure for this sale can be found here. Insiders sold 23,879 shares of company stock worth $2,926,931 in the last 90 days. 7.80% of the stock is owned by company insiders.

Several equities research analysts have issued reports on UTHR shares. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. TheStreet downgraded United Therapeutics Corporation from a “b-” rating to a “c” rating in a report on Friday, September 29th. Cowen and Company reiterated a “hold” rating and set a $129.00 price objective on shares of United Therapeutics Corporation in a research report on Friday, October 27th. Finally, HC Wainwright reiterated a “hold” rating and set a $95.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, October 26th. Five analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $132.82.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.